Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Disease area: Airway diseases

Abstract

Background: Asthma symptom control is a primary goal. Administrative data has been used to quantify the amount of medication use in order to identify in-risk asthma patients.Methods: We detected all patients who purchased SABA inhalers during one year. Primary physicians identified asthma patients and classified their asthma symptom control. Asthma patients were asked to answer symptom questionnaires and grade their asthma control. SABA inhalers purchases were compared between asthma control groups as was classified by the guidelines, the physicians and the patients. Results: Of the 241 asthma patients 83 completed the questionnaires. Using the GINA guidelines criteria, 26 were symptom controlled, 46 were partially controlled and 11 were uncontrolled. SABA inhalers purchase was non-significantly lower in the controlled group. Using patient overall impression of asthma control we found statistically significant differences of 1.5, 4.4 and 6.4 mean SABA inhalers purchases in the controlled, partially controlled and uncontrolled group respectively (p=0.03).



Patients' classification of asthma control had better agreement (kappa = 0.34) with GINA guidelines than physician's' agreement (kappa = 0.0511).Conclusion: We suggest that when using administrative data, 2 or more SABA inhalers purchase in one year should alert the physician for evaluate asthma control.


Rating:

Share or cite this content

Citations should be made in the following way:
Dekel Shlomi (Petah-Tiqwa, Israel), Dekel Shlomi, Irit Katz, Michael Segal, Nir Peled. Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase. Eur Respir J 2016; 48: Suppl. 60, 1042

Member's Comments

No comment yet.

Related content which might interest you: Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Description of the UK’s asthma and COPD inhaler use Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018 The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 A digital inhaler uncovering patterns of SABA use in asthma and COPD Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020 The asthmatic patient and inhaler treatment devices profile in Turkey: Asthma inhaler treatment study Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: a prescribing claims study of 2823 patients using a CFC - pMDI and a breath-actuated device Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 Pattern of asthma control and inhaled corticosteroid (ICS) use in an Australian asthma population Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Comparison of asthma and COPD patients' perception of appropriate metered-dose inhaler technique with a questionnaire and supervision based reference standard Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic. Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability Source: Eur Respir J 2002; 19: 246-251 Year: 2002 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 “My reliever helps me control my asthma”: patient attitudes to asthma inhalers Source: International Congress 2018 – The complexities of managing mild asthma Year: 2018 Comparing pharmacist time use for asthma and COPD patients using various types of inhaler devices Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Predictors of good inhaler technique in asthma and COPD Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007 Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013